title: Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
abstract: Cloretazine is an antitumor sulfonylhydrazine prodrug that generates both chloroethylating and carbamoylating species. The cytotoxic potency of these species was analyzed in L1210 leukemia cells using analogues with chloroethylating or carbamoylating function only. Clonogenic assays showed that the chloroethylating-only agent 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine (90CE) produced marked differential cytotoxicity against wild-type and O6-alkylguanine-DNA alkyltransferase-transfected L1210 cells (LC10, 1.4 versus 31 micromol/L), indicating that a large portion of the cytotoxicity was due to alkylation of DNA at the O-6 position of guanine. Consistent with the concept that O-6 chloroethylation of DNA guanine progresses to interstrand cross-links, the comet assay, in which DNA cross-links were measured by a reduction in DNA migration induced by strand breaks, showed that cloretazine and 90CE, but not the carbamoylating-only agent 1,2-bis(methylsulfonyl)-1-[(methylamino)carbonyl]hydrazine (101MDCE), produced DNA cross-links and that cloretazine caused more DNA cross-links than 90CE at equimolar concentrations. Cell cycle analyses showed that 90CE and 101MDCE at concentrations of 5 and 80 micromol/L, respectively, produced similar degrees of G2-M arrest. 90CE produced selective inhibition of DNA synthesis after overnight incubation, whereas 101MDCE caused rapid and nonselective inhibition of RNA, DNA, and protein syntheses. Both 90CE and 101MDCE induced phosphorylation of histone H2AX, albeit with distinct kinetics. These results indicate that (a) differential expression of O6-alkylguanine-DNA alkyltransferase in tumor and host cells seems to be responsible for tumor selectivity exerted by cloretazine; (b) 101MDCE enhances DNA cross-linking activity; and (c) 90CE induces cell death at concentrations lower than those causing alterations in the cell cycle and macromolecular syntheses.
authors.affiliation: Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
authors.forename: Kimiko
authors.initials: K
authors.lastname: Ishiguro
authors.forename: Helen A
authors.initials: HA
authors.lastname: Seow
authors.forename: Philip G
authors.initials: PG
authors.lastname: Penketh
authors.forename: Krishnamurthy
authors.initials: K
authors.lastname: Shyam
authors.forename: Alan C
authors.initials: AC
authors.lastname: Sartorelli
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000633:toxicity*; D002453:Cell Cycle / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects*; D020552:Comet Assay; D006657:Histones / Q000378:metabolism; D006834:Hydrazines / Q000737:chemistry* / Q000633:toxicity*; D007939:Leukemia L1210; D051379:Mice; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation; D011355:Prodrugs; D013449:Sulfonamides / Q000737:chemistry* / Q000633:toxicity*; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D006657:Histones; D006834:Hydrazines; D011355:Prodrugs; D013449:Sulfonamides; C483604:laromustine; D019853:O(6)-Methylguanine-DNA Methyltransferase